Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
08 juin 2020 08h05 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Receives Extension From Nasdaq to Satisfy Continuing Listing Requirements
04 juin 2020 16h05 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., June 04, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders
15 mai 2020 16h45 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders
08 mai 2020 09h00 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., May 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing...
Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results
06 mai 2020 08h05 HE
|
Aeterna Zentaris Inc.
– First quarter marked by positive results from AEZS-130-P01 (“Study P01”), of macimorelin, providing clinical framework to advance pediatric investigation plan (“PIP”) for macimorelin as a growth...
Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing
15 avr. 2020 16h06 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit
15 avr. 2020 09h15 HE
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN
07 avr. 2020 13h00 HE
|
Aeterna Zentaris Inc.
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol...
AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN
06 avr. 2020 09h00 HE
|
Aeterna Zentaris Inc.
– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Pediatric PK/PD profile of...
AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
30 mars 2020 17h00 HE
|
Aeterna Zentaris Inc.
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a...